Human butyrylcholinesterase (hBChE) is currently being developed as a detoxication enzyme for the catalytic hydrolysis or stoichiometric binding of organophosphates (OPs). Previously, rationally-designed hBChE mutants (i.e., G117H and E197Q) were reported in the literature and showed the feasibility of engineering OP hydrolytic functional activity into hBChE. However, the OP hydrolysis rate for G117H is too low for clinical utility. Additional OP-resistant hBChE variants with greater hydrolysis rates are needed as OP nerve agent countermeasures for therapeutic utility. As described herein, a directed molecular evolution process was used to identify amino acid residues that contribute to OP-resistant functional activity of hBChE variants. In this report, we describe the development and validation of a novel method to identify hBChE variants with OP-resistant functional activity (i.e., decreased rate of OPinhibition). The method reported herein utilized an adenoviral protein expression system combined with a functional screening protocol of OP nerve agent model compounds that have been shown to have functional properties similar to authentic OP nerve agent compounds. The hBChE screening method was robust for transfection efficiency, library diversity, and reproducibility of positive signals. The screening approach not only identified the previously reported hBChE G117H variant, but also identified a series of additional hBChE variants, including hBChE G117N, G117R, E197C and L125V, that exhibited OP-resistant functional activities not reported before. The mammalian functional screening approach can serve as a cornerstone for further optimization and screening for OP-resistant hBChEs for potential therapeutic applications.
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Introduction
The primary physiologically relevant target of organophosphate (OP) nerve agents and pesticides in the central nervous system (CNS) is acetylcholinesterase (AChE), and a prominent target in the periphery is butyrylcholinesterase (BChE) (Gupta 2006) . Currently available treatment for OP nerve agent poisoning includes combined administration of a cholinesterase (ChE) reactivator (i.e., an oxime), a muscarinic receptor antagonist (i.e., atropine), and an anticonvulsant (i.e., diazepam) (Fleisher and Harris 1965; Harris et al. 1966; Munro et al. 1990 ).
These treatments only act in a competitive fashion and are not adequate because they do not prevent brain damage and incapacitation. One attractive approach is to administer a detoxication enzyme that not only binds the OP but also hydrolyzes OP nerve agents before they reach the CNS and cause irreversible damage. Human BChE (hBChE) represents an ideal enzyme for enzyme supplementation therapy because it doesn't require cofactors, is soluble and highly functional at the pH of the plasma, and the products of its action are generally non-toxic. Further, wild type hBChE has been developed as a catalytic or stoichiometric OP detoxication scavenger (Lenz et al. 2010) . hBChE scavenges low doses of OP nerve agents by forming covalent bonds with these agents using a similar mechanism as AChE. Rationally-designed OP-resistant hBChE variants (i.e., G117H and E197Q) were reported and showed the feasibility of engineering OP hydrolytic functional activity into hBChE 8 . However, the OP hydrolysis rate of hBChE G117H is too low for clinical utility. OP-resistant hBChE variants with greater hydrolysis rates are needed as nerve agent countermeasures.
Previous biochemical efforts employed to search for a ChE designed to efficiently facilitate OP nerve agent hydrolysis have mainly focused on mutagenesis of selected amino acids based on Xray structure analysis (Millard et al. 1995; Shafferman et al. 1996; Lockridge et al. 1997; Introduction of E197Q into an hBChE variant, was shown to slow down enzyme aging, a process where OP-adducts lose one or more of their alkyl moieties by spontaneous hydrolysis (Millard et al. 1998; Li et al. 2007 ). The hydrolysis rate for soman, sarin and VX is increased 200-, 1400-, and 4700-fold, respectively, for the G117H/E197Q double mutant variant (Millard et al. 1998 ).
In addition, both D70 and W82 of hBChE were found to be important for irreversible aging (Masson et al. 1997) . It was proposed that W86 of AChE contributes to the aging process by stabilizing the putative carbonium ion on the 1,2,2-trimethylpropyl moiety of soman, and E202
and F338 apparently contribute to the aging process by stabilizing the imidazolium ion of the catalytic triad H447 (Shafferman et al. 1996) . Mutations of F338, W86, N74, and mutants of the hydrogen-bond network E202, E450, Y133 in AChE all showed resistance to aging (Shafferman et al. 1996) . Apparently, the molecular basis for efficient ChE OP hydrolytic functional activity is distributed throughout a number of residues in the primary sequence of the protein.
As described herein, we employed a directed molecular evolution approach to identify residues of hBChE that can markedly improve its OP hydrolytic functional activity. In this report, we describe the development and validation of a novel screening method that identified hBChE variants with a decreased rate of inhibition by OPs. Because the use of chemical warfare agents is strictly regulated, we utilized nerve agent model compounds that have been shown to have similar functional properties to authentic OP compounds (Barakat et al. 2009; Gilley et al. 2009 ).
OP model compounds not only served as a useful means to screen hBChE variants in molecular JPET #198499 6 evolution screening, but also was used in kinetic studies of variants identified (Ralph et al. 2011 ).
The hBChE screening method was assessed for its robustness, including transfection efficiency, library diversity, and reproducibility of positive signals. The method not only could identify the known hBChE G117H variant from among the library members, but also identified G117N, G117R, E197C and L125V hBChE variants that have not been reported before. With the help of a newly developed His-tag protein purification procedure (Ralph et al. 2011) , we investigated the kinetics of many identified hBChE variants. The molecular evolution screening method described herein thus can serve as a cornerstone for further optimization and screening for OPresistant hBChEs in a mammalian protein expression system.
Methods
Biological and chemical reagents
Butyrylthiocholine iodide (BTC), acetylthiocholine (ATC) and 5, 5'-dithiobis (2-nitrobenzoic acid) (DTNB) were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO). BES-Thio (2, 4-dinitrobenzenesulfonyl fluorescein) was synthesized following procedures described previously (Maeda et al. 2005) . Goat anti-rabbit antibodies conjugated with horseradish peroxidase enzyme (HRP) and Supersignal West Pico Chemiluminescent substrate was purchased from Pierce (Rockford, IL). HRP-conjugated goat anti-adenovirus serum was purchased from ViroStat (Portland, ME). Buffers and solvents were purchased from VWR Scientific, Inc. (San Diego, CA) in the highest purity commercially available. Molecular biology reagent was purchased from Life Technologies (Carlsbad, CA) unless otherwise specified.
Highly purified hBChE, anti-BChE polyclonal antibodies, echothiophate iodide (2- 
trimethylammoniumethyl) methylphosphonothioate iodide) (S p GB-C) and S p GA-C were synthesized as previously described (Berman and Leonard 1989; Barakat et al. 2009 ). The nerve agent model compounds are toxic and should be handled with extreme care. Chemical waste containing these nerve agent model compounds was degraded by hydrolysis by overnight incubation with 2.5 M NaOH and 10% ethanol before disposal.
Cell culture
HEK 293A cells were purchased from ATCC (Manassas, VA). HEK 293A cells were cultured in DMEM medium (Life Technologies) containing 8% FBS (Life Technologies) during passage and seeding. The media was exchanged to serum-free media when culture media was used for enzyme assays to avoid interference from bovine AChE from the serum. The adenovirus vector system is based on the adenovirus serotype 5 genome that contains no E1 and E2A regions (Gorziglia et al. 1996) . For recombinant virus packaging, two cell lines were used, 293A and EC7, both of which carry the E1 and E2A gene. These features allowed the production of 
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Construction of hBChE mutation libraries
One site-saturation mutation library (library 0) and six random mutation libraries (libraries 1-6),
were constructed for the current study using PCR, cloning, and transfection procedures. First, mutations were introduced through PCR amplification using mutation primers (Supplemental Table 1 ). Site-saturation mutagenesis at DNA corresponding to amino acids G117 and E197 of hBChE was achieved through PCR using oligonucleotide primers listed in Supplemental Table   1 . Three separate PCR reactions were done using the primer pairs KpnI_F/117_R, 117_F/197_R
and 197_F/XhoI_R. The PCR products obtained were extracted from an agarose gel and the purified fragments were combined and used as templates in PCR reactions using primer pair KpnI_F/XhoI_R to produce full length hBChE genes. For random mutation library 1, two separate PCR reactions using primer pairs Kpn_F/I_R, and I_F/Xho_R were used. The PCR products obtained were extracted from the agarose gel and combined as a template in PCR reactions using primer pair KpnI_F/XhoI_R to produce a full length hBChE gene. Random mutation libraries 2-6 were generated through PCR as described above using corresponding primers listed in Supplemental Table 1 .
The full length PCR fragments from each library were cloned into pENTR1A vector (Life Technologies) through KpnI and XhoI sites and transformed into the electro-competent 10B cells (Bio-Rad, Hercules, CA). Twenty random clones were sequenced to verify the introduction of the mutation. Approximated 5000 colonies from the pENTR1A cloning transformation were pooled for plasmid preparation to obtain mutation libraries in pENTR1A. A LR Clonase II (Life Technologies) recombination reaction was done between the pENTR1A-BChE library and the pAd/CMV/V5-DEST vector following the manufacturer's instructions (Life Technologies).
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Recombination reaction products were transformed into electro-competent 10B cells (Bio-Rad).
Twenty clones were randomly selected and sequenced to verify the presence of the mutation.
Approximated 10 5 colonies from the recombination transformation were pooled for plasmid preparation to obtain the mutation library in pAD.
Generation of recombinant adenovirus using ViraPower Adenovirual Gateway Expression system was achieved following the manufacturer's instructions (Life Technologies). Briefly, adenovirus plasmids encoding hBChE genes were linearized with Pac I digestion and transfected into EC7 cells pre-seeded in 10 cm culture plates using Lipofectamine 2000. Recombinant virus generation was monitored based on the appearance of a cytopathic effect (CPE). Cells were lysed with three freeze-thaw cycles and recombinant viruses released into the medium were collected by filtration through a 0.22 µm filter. The primary recombinant AD library stock was stored in -80 °C in small aliquots.
Recombinant virus encoding wild type (WT) hBChE and G117H variant enzymes were generated through subcloning hBChE gene fragments into KpnI and XhoI sites of pENTR1A, recombination into pAd/CMV/V5-DEST, and transfection after Pac I linearization was done as described for the library construction except that single colonies were isolated at each stage of the cloning process. were cored out using a wide-orifice pipette tip and stored in PBS. Gel plugs served as a starting point for material in the following liquid-phase screening.
Virus titer determination and amplification
Liquid-phase screen for OP-resistant variants JPET #198499
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For confirmation of OP-resistant hBChE variants identified from the solid-phase screens, isolated virus was amplified by infecting HEK 293A cells. The hBChE gene products from the virus identified in the screen as "hits" were amplified through PCR using primer pairs KpnI_F/Xho_R and then prepared for sequence analysis. The enzyme variant that was identified as a "hit" was expressed through infection in 500 µl CHO-CAR suspension cells at a density of was determined by BTC activity measurement. To harvest the secreted protein, cell pellet was removed by centrifugation at 30,000 x g for 30 minutes. The supernatant was concentrated by using a 10 KD MWCO filter (Millipore, Bedford, MA) and dialyzed with Buffer A (20 mM sodium phosphate pH 8, 1 mM EDTA) two to three times. The proteins were concentrated through filtration and then used for kinetic analysis using BTC as a substrate.
Adenovirus-mediated hBChE protein expression
Human WT BChE and G117H variant enzymes were expressed in CHO adherent or CHO-cTA- 
Enzyme assays
As previously described (Barakat et al. 2009 ), AChE and BChE functional activity was measured spectrophotometrically (Lambda 25, Perkin-Elmer, Palo Alto, CA) with an Ellman assay (Ellman et al. 1961 ). Briefly, ATC or BTC was used as a substrate for AChE and BChE, respectively, at 1 mM final concentration. The incubations were carried out in 50 mM potassium phosphate buffer (pH 7.2) at 25°C in the presence of 0.2 mM DTNB. Hydrolysis was followed continuously by monitoring absorbance at 412 nm. Functional activity was calculated using the molar extinction coefficient of 13,600 M -1 cm -1 (Ellman et al. 1961 )
Determination of inhibition rate constants (k inh ) for AChE and BChE
To prevent loss of ChE enzyme activity during incubation, 30 µg/ml of bovine milk β -lactoglobulin was included in the enzyme-inhibitor incubation mixture. Nerve agent model compounds were placed in acetonitrile (ETP, Paraoxon) or DMSO (SpGD, SpGB, SpGF, or SpGAc) and then diluted in H 2 O before use. Final solvent concentration in the inhibition mixtures was < 5%. Control experiments showed no impact on enzyme activity with 5% solvent or less in the incubation mixture (i.e., BChE or AChE incubated with 30 µg/ml bovine milk β -lactoglobulin in 10 mM Tris buffer pH 7.6 at 25°C plus 5% acetonitrile or DMSO). The inhibition mixtures were incubated at 25°C, and aliquots were withdrawn at defined times (every 2 min) to determine functional activity. The rates of BTC hydrolysis were measured using an Ellman assay described above in Enzyme assays. The observed apparent rates of BTC hydrolysis were fit to a single-phase decay (using Prism software, GraphPad Prism, San Diego, CA) as a function of the incubation time with OP to yield apparent rates of inhibition (k inh ).
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In the enzyme kinetic studies, the data was analyzed with GraphPad Prism version 5.01
(GraphPad Inc).
Results
Design and construction of highly diversified mutation libraries of human BChE
As shown in the cartoon model (Figure 1A) , the active site of hBChE contains a traditional esterase catalytic triad S198-E325-H438 that lies near the bottom of a deep and narrow gorge ( Figure 1A) . Because a successful molecular evolution approach is dependent on the diversity and size of the random mutagenesis library, six critical structurally relevant regions were selected for targeted random mutagenesis ( Figure 1B) . The design of the libraries incorporated structural information known about hBChE (Cokugras 2003) and allowed generation of a set of focused mutation libraries. Together with previously identified mutation sites (i.e., G117 and E197), that were used as a positive control (library 0, an independent library distinct from libraries 1-6, Figure 1B to validate the overall functional screening process), we designed 7 libraries in total ( Figure 1B ) that covered different regions of the active site pocket of hBChE as shown in Figure   1B .
PCR mutagenesis and library diversity validation
As shown in Figure 2 , the hBChE library construction involved four stages: 1) introduction of mutations through PCR using doped oligonucleotides; 2) subcloning of PCR library fragments into the shuttle vector pENTR1A; 3) transfer of the mutation library from pENTR1A to pAD through recombination; and 4) packaging of the mutation libraries in pAD in recombinant AD particles through transfection. In stage 1, mutagenesis of the hBChE gene was done through PCR with primers that had proportionally doped nucleotides (i.e., 96% wild type, 4% NNK) to codon (i.e., MNN for antisense primers). In practice, the doped primers contained nucleotide changes that could be translated into approximately 1-2 random amino acid substitutions among the 120 targeted residues within each of the six primers. The diversity of library 0 was defined to be 1024 (i.e., saturation mutagenesis at 2 positions by incorporating NNK was 32 x 32 = 1024).
The target diversity of the mutation libraries 1-6 was also ~1000 (i.e., randomization of 20 residues through 1-1.5 mutations). The number of colonies recovered at each stage of the subcloning steps (i.e., stages 2 and 3) were >5000 colonies for library 0 and >10 4 colonies for libraries 1-6 and ensured a good statistical coverage of the diversity of the libraries.
At stage 4, for adenovirus packaging, a titer of >10 7 infection units (i.u.) was routinely achieved at 4 days post-transfection for a typical 10 µg linearized pAD library DNA. The results of parallel control transfection studies with a spike of 0.1% (g/g) of a pAD-LacZ construct allowed consistent recovery of pAD-LacZ. This result confirmed that >1000 virus packaging events/transfection was achieved with HEK293A cells to ensure that the complexity of the library was maintained at the recombinant virus stage. The diversity of the mutation library was also verified based on DNA sequence analysis of Stage 1 PCR products by sequencing random colonies from stage 2 and 3 subclones, and from sequencing DNA from random virus after limited dilution. Representative sequencing results (Table 1) showed that the mutation rate was 1.8% in nucleotides and 3.8% in amino acids.
Functional screening for OP resistant hBChE variants
This article has not been copyedited and formatted. The final version may differ from this version. In the functional screening assay for hBChE variants possessing OP resistance (i.e., decreased rate of inhibition by OP), (steps 1-5, Figure 3) , both 'solid phase screening' and 'liquid phase screening' techniques were used with full-length hBChE. In solid phase screening (step 1, Figure 3 ), gel plugs that gave bright yellow positive signals from the Ellman assay (i.e., plates were incubated with OP for 2 to 6 hours, followed by incubation with 1 mM butyrylthiocholine (BTC) and 1 mM of DTNB, that gave rise to the yellow color of 2-nitro-5-thiobenzoate when the disulfide bond of DTNB was cleaved by the thiol group of BTC) were identified and isolated by punching a hole on the agarose gel with large pore pipettes. To confirm the positive Ellman assay results from solid phase screening, a liquid-based method was developed. Virus particles isolated from gel plugs were used to infect cells cultured in 96 well plates to get amplified virus and then used to confirm the observed OP resistance in an Ellman assay. This method was referred to as 'liquid screening' (step 2, Figure 3) . In liquid phase screening, amplified virus was serially diluted and used for functional BTC hydrolysis activity assays. The assays were done in the presence of 1 mM BTC and 1 mM DTNB for 10 min in 50 mM PBS buffer (pH 7.4). Virus from the incubation where enzyme was expressed that showed OP inhibition on the basis of the BTC assay was diluted, re-infected and amplified cells were used to isolate DNA. The viral DNA was sequenced to identify the sites where mutagenesis was observed (steps 3-5, Figure 3 ).
Mutagenesis Studies
The initial hBChE molecular evolution library constructed, (i.e., library 0), was a site-saturated mutagenesis control library targeting two residues simultaneously (i.e., both G117 and E197
were mutagenized at the same time). Amino acid substitutions at these positions of hBChE, including G117H and G117H/E197Q have previously been shown to be associated with acquired OP-resistant activity as well as a low level of OP hydrolysis functional activity (Lockridge et al.
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binding ligand in affinity chromatography (Masson and Lockridge 2010) . In addition, because hBChE variants can possess even lower affinity to procainamide than wild type enzyme a new expression and purification procedure was developed (Ralph et al. 2011) . Thus, positive variants identified in the screens were cloned into pENTR1A and pAD vectors using a truncated version with a His-tag at the C-terminus. As reported previously, utilization of the His-tag facilitated protein production, purification, and robust kinetic studies (Ralph et al. 2011) . By using this approach, relatively large amounts of highly purified hBChE variant protein were obtained that was used in kinetic studies.
Kinetic studies of hBChE variants identified from screening libraries 0-6
As shown on the basis of the data in Table 3 , hBChE variants including G117H, G117R, G117N, E197C, and L125V that were identified using the OP-resistance functional screening method described above were evaluated using in vitro kinetic studies. In contrast to the screening process described above, for kinetic analysis of the variants identified it was more expedient to use His-tag truncated hBChE variants. Highly purified His-tag truncated hBChE variants including G117H, G117R, G11N and E197C from the site-saturation mutagenesis library 0 were analyzed for the rate of substrate hydrolysis using a modified Ellman assay. Representative progress curves for hydrolysis of BTC for the identified variants G117H, G117R, G11N and E197C are shown in Figure 5A -C and representative progress curves for hydrolysis of acetylthiocholine (ATC) are shown in Figure 5D -F. Kinetic parameters for the variants identified were determined by fitting the observed rates of hydrolysis for both substrates to the In a previously published study, it was reported that rationally designed variants of hBChE (i.e., G117H and E197Q) could hydrolyze P R/S C R , P S C S , and P R C S soman stereoisomers with apparent rate constants of 0.006, 0.077, and 0.128 min -1 , respectively (Millard et al. 1998 ). Thus, while hBChE variants have the potential to show OP hydrolase functional activity (Millard et al. 1995; Millard et al. 1998) , the OP hydrolysis rate for soman is too low for practical use or clinical utility. Previous efforts were focused on using a rational design based on the hBChE protein structure to design and develop an OP hydrolase (Shafferman et al. 1996; Lockridge et al. 1997; Saxena et al. 1997; Millard et al. 1998; Cokugras 2003) .
Using a molecular evolution approach to efficiently identify OP-resistant variants, a screening method was designed and developed to begin to identify amino acid residues involved in hBChE OP hydrolase functional activity. As an unbiased approach, a directed molecular evolution screen is an ideal approach to identify individual and multiple amino acid residues that are required to markedly improve OP hydrolytic functional activity of hBChE. In contrast to evolution of bacterial OP hydrolase (Cho et al. 2002) , molecular evolution of hBChE is more challenging because hBChE is a glycoprotein that requires mammalian cell expression for functional activity (Millard and Broomfield 1992) . Accordingly, development of an efficient expression system to identify OP-resistant variants using a functional screening approach was developed in mammalian cells.
Thus, we developed a procedure that included: 1) high level protein expression in the intended screening system; 2) an efficient cloning method to construct the mutation library; and 3) an efficient gene recovery method so that after the functional screen, the identification of the DNA sequence and any variants could be readily accomplished. Our screening method used an adenoviral protein expression system combined with nerve agent model compound functional
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identified not only from the site saturation mutagenesis library (library 0) as expected, but also from library 1, which was irrelevant to amino acid position 117 (Figure 1 ).
Combined with available structural information for hBChE, we designed 6 libraries to cover most regions that were known to be important in the active site of hBChE or that impinged on the active site of hBChE (Figure 1) . These regions not only included the gorge/substrate binding regions, but also included the active site itself that has the catalytic triad S198-D325-H438 and regions that can facilitate substrate binding (i.e., PAS/Omega loop and Acyl pocket). However, after functional screening, we identified only a handful of OP resistant variants (Table 2, Figure   7 ). Furthermore, most of them (11 out of 14) were recognized as previously reported mutation sites (i.e., G116, G117 or E197) (Millard et al. 1995; Lockridge et al. 1997) , suggesting the importance of those single amino acids in mediating protein functional change during directed evolution. Amino acid 117 in hBChE is part of the oxyanion hole (i.e., G116, G117 and A199)
that can stabilize the substrate or the transition state during ester hydrolysis (Lockridge et al.
1997).
When Gly 117 is replaced by Arg (G117R) or Asp (G117N), OP resistance is not as strong as when a His at position 117 is present. It is possible that G117H has stronger OP resistance due to its two hydrogen bonds with substrate instead of only one in the case of G117R or G117N (Lockridge et al. 1997; Schopfer et al. 2004) , Figure 7B-D) . Although most variants identified in this study are well known hBChE variants, we did identify some new variants (i.e., L125V, N68D) that have not been reported before. Although L125V showed an increased K m when BTC was used as substrate compared to G117H (1500 µM vs. 220 µM respectively, Table 3 ), it showed a very low K m (80 µM vs. 1200 µM respectively, Table 3 ) when ATC was used as substrate ( Table 3) . This suggests that L125V has a different mechanism in mediating substrate
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JPET Fast Forward. Published on September 6, 2012 as DOI: 10.1124 at ASPET Journals on April 6, 2017 jpet.aspetjournals.org Downloaded from hydrolysis compared to the G117H variant (Lockridge et al. 1997) . The localization of L125 in hBChE close to the entry site to the gorge ( Figure 7E) suggests that it might function in facilitating the initial binding of substrate. The data suggests that the screening platform is valid for identifying new variants in addition to previously identified variants (i.e., G117H) and the new variants can also serve as intermediates for future screening and optimization to ultimately afford additional novel variants.
Taken together, the method reported herein not only identified the previously reported hBChE G117H variant, but also identified G117N, G11R, E197C and L125V, hBChE variants that have not been reported before. The molecular evolution screening method can serve as a cornerstone for further optimization and screening for OP-resistant hBChEs in a mammalian protein expression system. This article has not been copyedited and formatted. The final version may differ from this version. plugs were used to infect cells cultured in 96 well plates to confirm OP resistance. Viruses that were confirmed to be OP-resistant variants were further purified and sequenced to identify the site of mutation. Variants were subcloned, expressed, purified and studied further in in vitro incubations to characterize their kinetic parameters. 
